Article
The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas - 1 Dec 2007
França P H C, Coelho H S M, Brandão C E, Segadas J A, Quintaes R F, Carrilho F J, Ono-Nita S, Mattos A A, Tovo C, Gouvea V S, Sablon E, Vanderborght B O M
Abstract excerpt
Given the loss of therapeutic efficacy associated with the development of resistance to lamivudine (LMV) and the availability of new alternative treatments for chronic hepatitis B patients, early detection of viral genotypic resistance could allow the clinician to consider therapy modification before viral breakthrough and biochemical relapse occur. To this end, 28 LMV-treated patients (44 +/- 12 years; 24 men),...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.